Table 4 Retrospective studies evaluating the use of salvage ASCT in relapsed multiple myeloma
Study | No. | ORR (%) | Median PFS (months) | Median OS (months) | TRM (%) |
|---|---|---|---|---|---|
Shah et al. [111] | 44 | 90 | 12.3 | 31.7 | 2 |
Jimenez-Zepaeda et al. [110] | 81 | 97 | 16.4 | 53 | 3 |
Olin et al. [116] | 41 | 55 | 8.5 | 20.7 | 7 |
Fenk et al. [114] | 55 | 75 | 14 | 52 | 5 |
Alvares et al. [120] | 83 | — | 15.6 | 34.8 | — |
Burzynski et al. [115] | 25 | 64 | 12 | 19 | 8 |
Mehta et al. [133] | 42 | 81 | 12.5 | 32 | 10 |
Eliece et al. [117] | 26 | 69 | 14.8 | 38.1 | 0 |
Gonsalves et al. [107] | 98 | 86 | 10.3 | 33 | 4 |
Yhim et al. [119] | 48 | — | 18 | 55.5 | — |
Lemieux et al. [108] | 81 | 93 | 18 | 48 | 0 |
Michaelis et al. [109] | 187 | — | 3-year PFS: 13% | 3-year OS: 46% | 2 |
